These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37507044)

  • 41. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
    Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
    J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Boosting immune system against cancer by melatonin: A mechanistic viewpoint.
    Mortezaee K; Potes Y; Mirtavoos-Mahyari H; Motevaseli E; Shabeeb D; Musa AE; Najafi M; Farhood B
    Life Sci; 2019 Dec; 238():116960. PubMed ID: 31629760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antitumor effects of immunity-enhancing traditional Chinese medicine.
    Wang Y; Zhang Q; Chen Y; Liang CL; Liu H; Qiu F; Dai Z
    Biomed Pharmacother; 2020 Jan; 121():109570. PubMed ID: 31710893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity.
    Singh A; Anang V; Kumari K; Kottarath SK; Verma C
    Prog Mol Biol Transl Sci; 2023; 194():269-310. PubMed ID: 36631195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NK cells and solid tumors: therapeutic potential and persisting obstacles.
    Tong L; Jiménez-Cortegana C; Tay AHM; Wickström S; Galluzzi L; Lundqvist A
    Mol Cancer; 2022 Nov; 21(1):206. PubMed ID: 36319998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives.
    Ashrafizadeh M; Farhood B; Eleojo Musa A; Taeb S; Najafi M
    Int Immunopharmacol; 2020 Oct; 87():106807. PubMed ID: 32683299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
    Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
    J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cekic C; Day YJ; Sag D; Linden J
    Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy.
    Starska-Kowarska K
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
    Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
    Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
    Wu Y; Yi M; Niu M; Mei Q; Wu K
    Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ru(II)-modified TiO
    Zhou JY; Wang WJ; Zhang CY; Ling YY; Hong XJ; Su Q; Li WG; Mao ZW; Cheng B; Tan CP; Wu T
    Biomaterials; 2022 Oct; 289():121757. PubMed ID: 36058028
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulatory cells and the effect of cancer immunotherapy.
    Iglesias-Escudero M; Arias-González N; Martínez-Cáceres E
    Mol Cancer; 2023 Feb; 22(1):26. PubMed ID: 36739406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
    Kochin V; Nishikawa H
    Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells.
    Mu Q; Najafi M
    Int Immunopharmacol; 2021 Sep; 98():107895. PubMed ID: 34171623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
    Bruno A; Mortara L; Baci D; Noonan DM; Albini A
    Front Immunol; 2019; 10():771. PubMed ID: 31057536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.